A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

[1]  J. Grem,et al.  Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Zarrabi,et al.  Preclinical and clinical evaluation of 5‐fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma , 1995, Cancer.

[6]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[7]  R. Schilsky,et al.  Laboratory and clinical studies of biochemical modulation by hydroxyurea. , 1992, Seminars in oncology.

[8]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[9]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[10]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Bleyer,et al.  New vistas for leucovorin in cancer chemotherapy , 1989, Cancer.

[12]  F. Valeriote,et al.  In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. , 1980, Journal of the National Cancer Institute.

[13]  C. Heidelberger,et al.  Fluorinated pyrimidines. , 1963, Progress in nucleic acid research and molecular biology.